Health News

ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon’s UltraVector Technology.

Read more

Filed under: Pharmacy News
Tags: DNA, Drug, Oncology, Pharmacy

Related posts

• ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate. Read more [tags] Pharmacy News [/tags]
  
  
• FDA accepts ZIOPHARM’s IND for ZIN ATI-001 to treat melanoma (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology. Read more [tags] [...]
  
  
• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]
  
  
• Æterna Zentaris commences perifosine Phase 3 registration trial (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer. Read [...]
  
  
• ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model. Read more [tags] Pharmacy News [/tags]